(Q33951444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Motility-modifying agents and management of disorders of gastrointestinal motility (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1

J E Pandolfino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

C W Howden

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

P J Kahrilas

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

2 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

S32-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

Histopathologic features in esophagomyotomy specimens from patients with achalasia

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Pathophysiology of achalasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Diffuse esophageal spasm. A rare motility disorder not characterized by high-amplitude contractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Diffuse esophageal spasm: a reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of nitrates on LOS pressure in achalasia: a potential therapeutic aid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Treating achalasia: from whalebone to laparoscope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

One man's poison--clinical applications of botulinum toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Intrasphincteric botulinum toxin for the treatment of achalasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Transient lower esophageal sphincter relaxation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Esophageal peristaltic dysfunction in peptic esophagitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

The epigastric pain in duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Lack of effect of metoclopramide and domperidone on esophageal peristalsis and esophageal acid clearance in reflux esophagitis. A randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Treatment of severe reflux esophagitis with cimetidine and metoclopramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Clinical pharmacology forum: motility agents and the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of cisapride on distal esophageal motility in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cisapride stimulates human esophageal motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of cisapride on the gastro-oesophageal function in normal human subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of cisapride, a new prokinetic agent, on esophageal motor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

A comparison of five maintenance therapies for reflux esophagitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Gastro-oesophageal reflux disease in adults and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cisapride vs metoclopramide. An acute study in diabetic gastroparesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of metoclopramide on normal and delayed gastric emptying in gastroesophageal reflux patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Induction of the fed pattern of human exocrine pancreatic secretion by nutrients: role of cholecystokinin and neurotensin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of trimebutine maleate on gastric motility in patients with gastric ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Receptor for motilin identified in the human gastrointestinal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of leucine 13-motilin (KW5139) on early gastric stasis after pylorus-preserving pancreatoduodenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Gastric myoelectrical activity in patients with gastric outlet obstruction and idiopathic gastroparesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Irritable bowel syndrome: a technical review for practice guideline development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of dopaminergic blocking agents on distal colon motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Colon motility and colo-anal reflexes in chronic idiopathic constipation. Effects of a novel enterokinetic agent cisapride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Large-intestine colic due to sympathetic deprivation; a new clinical syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Ogilvie's syndrome: a new approach to an old problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Early resolution of Ogilvie's syndrome with intravenous neostigmine: a simple, effective treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Neostigmine for the treatment of acute colonic pseudo-obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of sennosides on colon motility in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Esophageal sensitivity and symptom perception in gastroesophageal reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Esophageal dysfunction in syndrome X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Visceral analgesics and functional dyspepsia: have we found the Holy Grail?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Symptoms and visceral perception in severe functional and organic dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Association between H. pylori, duodenal mechanosensory thresholds, and small intestinal motility in chronic unexplained dyspepsia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Role of impaired gastric accommodation to a meal in functional dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Response to intraluminal gas in irritable bowel syndrome. Motility versus perception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Symptom relief with amitriptyline in the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Pharmacological stimulation of gastrointestinal motility: where we are and where are we going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

Basic and clinical aspects of visceral hyperalgesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970005-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(00)70005-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868897%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference